FDA Inspection 1040504 — Samson Pharmaceuticals, Inc

Samson Pharmaceuticals, Inc — FEI 3005644727

The FDA completed an inspection of Samson Pharmaceuticals, Inc on February 9, 2018 in Commerce, CA. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 16 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
February 9, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Commerce, CA (United States)

Citations

IDCFRDescription
119421 CFR 211.42(c)Defined areas of adequate size for operations
142121 CFR 211.42(c)(10)Aseptic Processing Area
143021 CFR 211.42(c)(10)(i)Floors, walls, ceiling surfaces
145121 CFR 211.113(b)Procedures for sterile drug products
180921 CFR 211.160(a)Following/documenting laboratory controls
183321 CFR 211.84(d)(1)Identity Testing of Each Component
185121 CFR 211.84(e)Rejecting When Specifications Not Met
189021 CFR 211.165(e)Test methods
358521 CFR 211.110(a)Control procedures to monitor and validate performance
359221 CFR 211.110(c)In-process materials characteristics testing
361321 CFR 211.160(b)(4)Establishment of calibration procedures
361621 CFR 211.165(d)Acceptance criteria for sampling & testing
363221 CFR 211.170(b)Annual visual exams of drug products
434221 CFR 211.142(b)Storage under appropriate conditions
435621 CFR 211.166(b)Tentative expiration date
439121 CFR 211.180(e)(2)Items to cover on annual reviews